Journal Club: Intravenous multipotent adult progenitor cell treatment decreases inflammation leading to functional recovery following spinal cord injury
Written by DePaul, et al. in the journal Scientific Reports. The complete article is here.
Background: Stem cells are unique in that they can divide indefinitely and can turn into multiple different types of cells (see image below). For example, during human development, embryonic stem cells have the ability to turn into all of the different cell types throughout the body – such as liver cells, lung cells, and skin cells. Embryonic stem cells are called pluripotent stem cells for this reason. Stem cells have also been found in adults, but they are usually able to turn into only one or several types of cells (called multipotent stem cells). Scientists have thought that this ability for stem cells to continually grow and turn into different cell types could be harnessed to treat a number of diseases that involve cell death, including spinal cord injury.
The authors of this paper are interested spinal cord injury (SCI). When the spinal cord (the bundle of nerves that goes down your back) is injured when something disrupts the vertebrae (like it being hit during a car accident) this can tear or push on the spinal cord. This causes damage to the nerves and prevents electrical signals between the body and the brain from being transmitted properly, often resulting in paralysis. The authors were interested in studying whether stem cells could help reverse the damage that’s caused by this type of injury.
Results: In this publication, the authors isolate stem cells called multipotent adult progenitor cells (MAPCs) from the bone marrow. To break this down, “multipotent” means that the stem cells can turn into several different cell types. “Progenitor” cells are actually more specified than stem cells – stem cells can divide forever, but progenitor cells can only divide a certain number of times. “Adult” means that these cells are taken from the adult bone marrow.
Because you can’t just inject cells into humans with spinal cord injury (that would have to be a clinical trial WAY down the road once there is evidence that it works in animals), the authors use a “model” of spinal cord injury in rats. Technically – they crush the rat’s spine (eek). In case you’re interested, here’s the device they use to do this. The rat then has decreased mobility and inability to urinate on it’s own – like what might happen in the case of a paralyzed person with a spinal cord injury.
The researchers injected multipotent adult progenitor cells into the rat after injury to see if they reverse these mobility and urination effects. Interestingly, when MAPCs are injected into a rat vein the day of injury, nothing happened. However, if the MAPCs are injected 1 day after injury, the rats recover some mobility and the ability to urinate on their own compared to rats without treatment.
One might assume that the MAPCs do this by going to the injured area of the spinal cord and re-growing nerve cells. However, the authors found that this wasn’t the case. In fact, the MAPCs moved to the outside edges of the injury and even more to the spleen (see image below). The spleen is where many of the body’s immune cells are stored. In spinal cord injury, the immune system is a double-edged sword. The immune system cleans up the damage from the injury itself but also attacks the injury and makes more damage. There is evidence from this paper that the MAPCs in the spleen decrease the damaging effect on the spinal cord injury from the immune cells in the spleen.
Conclusion: This paper presents a promising result that provides hope for this type of therapy in spinal cord injury patients.